EGFR

[Proceedings of the National Academy of Sciences of the United States of America] From an RNA interference (RNAi) screen in adult Drosophila intestinal stem cells (ISCs), researchers identified a factor, Yun, required for proliferation of normal and transformed ISCs.

[Scientific Reports] Scientists explored clinical factors in 332 advanced NSCLC who received EGFR TKI and molecular characteristics through 65 whole exome sequencing of various EGFR TKI responses including; de novo, intermediate response and long-term response.

[Signal Transduction and Targeted Therapy] Scientists identified two 4q12 long noncoding RNAs LCETRL3 and LCETRL4 which could significantly dimmish EGFR-TKIs efficiency.

[Cancer Discovery] Using metastatic models of EGFR-mutant lung cancer, the authors showed that cancer cells expressing high intracellular S100A9 escaped osimertinib and initiated brain relapses.

[ORIC Pharmaceuticals, Inc.] ORIC Pharmaceuticals, Inc. announced clearance of its Clinical Trial Application by the regulatory authorities of the Republic of Korea for ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations.

[Medical Oncology] Researchers employed a co-culture system to clarify the effects of human amniotic mesenchymal stromal cells secretome through tyrosine phosphorylation of c-Src, SGK223, AKT activity, and JAK1/Stat3 signaling in Panc1 pancreatic cancer cells.